SELLAS Life Sciences Group, Inc. (SLS)
NASDAQ: SLS · IEX Real-Time Price · USD
1.280
+0.040 (3.23%)
At close: May 1, 2024, 4:00 PM
1.220
-0.060 (-4.69%)
Pre-market: May 2, 2024, 8:08 AM EDT
SLS Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
16
Market Cap
72.02M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 0 | - | - |
Dec 31, 2022 | 1.00M | -6.60M | -86.84% |
Dec 31, 2021 | 7.60M | 5.70M | 300.00% |
Dec 31, 2020 | 1.90M | - | - |
Dec 31, 2019 | 0 | - | - |
Dec 31, 2018 | 0 | - | - |
Dec 31, 2017 | 0 | - | - |
Dec 31, 2016 | 0 | - | - |
Dec 31, 2015 | 0 | - | - |
Dec 31, 2014 | 0 | - | - |
Dec 31, 2013 | 0 | - | - |
Dec 31, 2012 | 0 | - | - |
Dec 31, 2011 | 0 | - | - |
Dec 31, 2010 | 0 | - | - |
Dec 31, 2009 | 0 | - | - |
Dec 31, 2008 | 0 | - | - |
Dec 31, 2007 | 0 | - | - |
Dec 31, 2006 | 0 | - | - |
Dec 31, 2005 | 0 | - | - |
Dec 31, 2004 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionSLS News
- 23 hours ago - SELLAS Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level - GlobeNewsWire
- 2 days ago - SELLAS Life Sciences Announces Positive Recommendation of Independent Data Monitoring Committee Following Completion of Enrollment in REGAL Phase 3 Study - GlobeNewsWire
- 4 weeks ago - SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update - GlobeNewsWire
- 5 weeks ago - SELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL Study - GlobeNewsWire
- 6 weeks ago - SELLAS Life Sciences Group Announces Closing of $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules - GlobeNewsWire
- 6 weeks ago - SELLAS Life Sciences to Host Corporate Update Call on March 26, 2024, at 8:15 am ET - GlobeNewsWire
- 6 weeks ago - SELLAS Life Sciences Group Announces $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules - GlobeNewsWire
- 7 weeks ago - SELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization Partnerships - GlobeNewsWire